Home/Fat Loss/Semaglutide

FAT LOSSFDA ApprovedGLP-1 AGONISTDIABETESWEIGHT LOSS

Semaglutide

Also known as: Ozempic · Wegovy · Rybelsus

89.4k views/week 2.1k citations 0 edits Updated 4/6/2026

Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is a modified human GLP-1 analog with a fatty acid side chain enabling once-weekly dosing via enhanced albumin binding.

STRUCTURE

Molecular Composition

FORMULA

C₁₈₇H₂₉₁N₄₅O₅₉

MOL. WEIGHT

4113.58 Da

SEQUENCE LENGTH

31 amino acids

CAS NUMBER

910463-68-2

HALF-LIFE

~7 days (weekly)

FDA STATUS

Approved (Ozempic/Wegovy)

AMINO ACID CHAIN VISUALIZATION

H

Histidine

GLP-1R recognition

—

NH-CO

A

Aib (α-methyl)

DPP-IV resistance

—

NH-CO

E

Glutamate

charge stabilization

—

NH-CO

G

Glycine

backbone flexibility

—

NH-CO

T

Threonine

receptor contact

—

NH-CO

K

Lysine*

C18 fatty acid anchor

—

NH-CO

R

Arginine

C-terminal stabilizer

SEQUENCEH-A-E-G-T-K-R

MECHANISMS

How It Works

🎯

GLP-1 Receptor Agonism

Semaglutide binds GLP-1R with ~94% homology to native GLP-1, providing the same glucose-dependent insulin secretion, glucagon suppression, and gastric emptying effects — but with a half-life of 7 days vs. 2 minutes for endogenous GLP-1. This continuous receptor engagement is the basis for its superior efficacy over earlier GLP-1 agents.

🧠

Central Appetite Suppression

GLP-1 receptors in the hypothalamic arcuate nucleus (ARC), paraventricular nucleus (PVN), and area postrema mediate powerful reductions in appetite and food reward. Semaglutide reduces hunger, increases satiety per meal, and reduces cravings for high-fat, high-calorie foods — independently of caloric restriction.

⏱️

Albumin Binding & Extended Half-life

A C18 fatty diacid chain is attached to lysine-26 via a linker, enabling >99% reversible albumin binding in plasma. This "depot" effect slows renal clearance and proteolytic degradation, extending the half-life from 2 minutes (native GLP-1) to ~7 days — enabling once-weekly subcutaneous or once-daily oral dosing.

❤️

Cardiovascular Protection

The SUSTAIN-6 and SELECT trials demonstrated significant reductions in major adverse cardiovascular events (MACE) in high-risk patients — a benefit beyond glycemic control. Mechanisms include direct GLP-1R effects on cardiomyocytes, vascular inflammation reduction, and indirect benefits from weight loss and blood pressure reduction.

OVERVIEW

Research Overview

Semaglutide was developed by Novo Nordisk and approved by the FDA in 2017 for type 2 diabetes management (Ozempic), and later in 2021 for chronic weight management at higher doses (Wegovy). It represents the clinical gold standard of GLP-1 receptor agonist therapy.

The key innovation of semaglutide over earlier GLP-1 analogs (like liraglutide) is a C-18 fatty acid chain attached via a linker to lysine at position 26. This enables >99% albumin binding in the bloodstream, dramatically extending its half-life to approximately 7 days — enabling once-weekly subcutaneous injection.

Mechanism of Action

// GLP-1 RECEPTOR AGONISM

Semaglutide binds to and activates GLP-1 receptors in the pancreas, stimulating glucose-dependent insulin secretion and suppressing glucagon release. Crucially, this effect is glucose-dependent — preventing hypoglycemia.

// CENTRAL APPETITE SUPPRESSION

GLP-1 receptors in the hypothalamus and brainstem mediate powerful appetite suppression. Semaglutide slows gastric emptying and directly reduces food intake by acting on satiety centers in the CNS.

SEQUENCE

Amino Acid Sequence

His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg

DOSAGE

Dosage & Administration

INJECTABLE (SUBCUTANEOUS) — OZEMPIC (T2D)

DOSE

0.25 mg → 0.5 mg → 1 mg → 2 mg (escalation)

FREQUENCY

Once weekly; escalate every 4 weeks

NOTES

FDA-approved for type 2 diabetes. Start at 0.25 mg for 4 weeks (tolerability), then 0.5 mg, escalate to 1–2 mg based on glycemic response. Inject into abdomen, thigh, or upper arm.

Calculate dose in Peptide Calculator

INJECTABLE (SUBCUTANEOUS) — WEGOVY (OBESITY)

DOSE

0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg (escalation)

FREQUENCY

Once weekly; escalate every 4 weeks over 17 weeks

NOTES

FDA-approved for chronic weight management. Target maintenance dose is 2.4 mg/week. Slower escalation schedule compared to Ozempic. Same injection technique — rotate sites weekly.

Calculate dose in Peptide Calculator

ORAL (RYBELSUS — T2D ONLY)

DOSE

3 mg → 7 mg → 14 mg

FREQUENCY

Once daily on an empty stomach. Wait 30 min before eating or drinking.

NOTES

First oral GLP-1 agonist. Bioavailability is ~1% oral vs. ~89% subcutaneous. Must be taken with up to 120 mL plain water only — food or other drinks dramatically reduce absorption. Escalate every 30 days.

Semaglutide is the global standard of care GLP-1 agonist. Nausea and vomiting are the most common side effects, most pronounced during dose escalation — eating smaller portions and avoiding fatty foods helps. A class warning exists for potential thyroid C-cell tumors (based on rodent data); avoid in personal/family history of MTC or MEN2. Do not combine with other GLP-1 agonists or use alongside other injectable diabetes medications without physician guidance.

CYCLING

Cycle Duration Guide

ON CYCLE

Continuous chronic use (not cycled — weight regain occurs upon cessation)

OFF CYCLE

No standard off-cycle. Tapering recommended before discontinuation.

Semaglutide is designed for long-term chronic use. STEP extension trial data shows weight regain of ~2/3 of lost weight within 1 year of discontinuation. Unlike research peptides that are typically cycled, GLP-1 agonists are maintained indefinitely in clinical practice when tolerated. If stopping, taper the dose over 4–8 weeks rather than abrupt cessation to minimize rebound appetite increase.

⚠

Do not use if personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Pancreatitis has been reported — discontinue and seek care if persistent severe abdominal pain occurs. Avoid in pregnancy.

View full Cycle Guide →

◆Quick Reference

FORMULAC₁₈₇H₂₉₁N₄₅O₅₉

MOL. WEIGHT4,113.58 Da

LENGTH31 amino acids

ORIGINSynthetic GLP-1 analog; C-18 fatty acid modification for extended half-life

HALF-LIFE~7 days (subcutaneous injection)

SOLUBILITYSoluble in water; supplied as pre-filled pen injector

CAS NO.910463-68-2

STATUSFDA Approved

Ask AI

Ask anything about Semaglutide — mechanisms, dosing protocols, interactions, or research comparisons.

TAGS

GLP-1 agonistdiabetesweight losscardiovascular

EXPLORE

Related Peptides

FAT LOSSGLP-1 AGONISTGIP AGONIST

Tirzepatide

Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…

0 citations0/wk

FAT LOSSFAT LOSSLIPOLYSIS

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…

0 citations0/wk

FAT LOSSAMYLIN ANALOGUEWEIGHT LOSS

Cagrilintide

Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…

0 citations0/wk

FAT LOSSMITOCHONDRIALINSULIN SENSITIVITY

MOTS-c

MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of the mitochondrial ge…

0 citations0/wk